Is this child bipolar? What’s needed to improve diagnosis
With genetic and brain imaging biomarkers, early intervention could protect at-risk kids.
DR. CHANG: Our research is trying to bypass that debate. We’re trying to understand whether biomarkers in the brain or blood can be used to distinguish different types of bipolar disorders, rather than relying on symptomatology.
Related resources
- Chang KD, Howe M, Gallelli, K, Miklowitz D. Prevention of pediatric bipolar disorder: integration of neurobiological and psychosocial processes. Ann NY Acad Sci 2006;1094:235–47.
- Chang KD, Gallelli KA. Bipolar disorders and genetics: clinical implications of high heritability. Medscape Psychiatry & Mental Health 2004;9(2). Available at: https://www.medscape.com/viewarticle/489331.
- Miklowitz D, Biuckians A, Richards JA. Early-onset bipolar disorder: a family treatment perspective. Dev Psychopathol 2006;18(4):1247–65.
- Carbamazepine • various
- Lamotrigine • Lamictal
- Lithium • Eskalith, Lithobid
- Methylphenidate • Ritalin
- Olanzapine • Zyprexa
- Quetiapine • Seroquel
- Valproate • Depakene, Depakote
Dr. Chang receives research support from AstraZeneca, Eli Lilly and Company, Otsuka, and the National Institute of Mental Health. He is a consultant to Abbott Laboratories, GlaxoSmithKline, and Shire, and a speaker for Abbott Laboratories and AstraZeneca.
Dr. Kowatch receives research support from Bristol-Myers Squibb, Stanley Research Foundation, National Institute of Mental Health, and National Institute of Child Health and Human Development. He is a speaker for Abbott Laboratories and AstraZeneca.
